Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53

Hematology

Volumn 19, Issue 4, 2014, Pages 225-231

  Wang, Li ^a   Luo, Jing ^a   Nian, Qing ^a   Xiao, Qing ^a   Yang, Zesong ^a   Liu, Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Myelodysplastic syndrome; P53; Proliferation; RPS14; Suppression

Indexed keywords

PROTEIN P53; RIBOSOME PROTEIN; RIBOSOME PROTEIN S14; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; RIBOSOMAL PROTEIN S14;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ASSAY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MRNA EXPRESSION ASSAY; MTT ASSAY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; COMPLICATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC THERAPY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; RIBOSOMAL PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84901423070     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845413Y.0000000127     Document Type: Article

References (23)

1. Boultwood J, Pellagatti A, Wainscoat JS. 5q- syndrome. Curr Pharm Des. 2012;18(22):3180-3.
2. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451(7176):335-9.
3. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2010;16(1):59-66.
4. Czibere A, Bruns I, Junge B, Singh R, Kobbe G, Haas R, et al. Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. Haematologica. 2009;94(10):1453-5.
5. Lane DP. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol. 2005;70:489-97.
6. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999;274(51):36031-34.
7. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001; 114(Pt 23):4139-40.
8. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human ery-throid progenitor cells. Blood. 2011;117(9):2567-76.
9. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-10.
10. Hofseth LJ, Hussain SP, Harris CC p53: 25 years after its discovery. Trends Pharmacol Sci. 2004;25(4):177-81.
11. Narla A, Ebert BL. Ribosomopathies: human disorders of ribo-some dysfunction. Blood. 2010;115(16):3196-205.
12. Scherr M, Eder M. Gene transfer into hematopoietic stem cells using lentiviral vectors. Curr Gene Ther. 2002;2:45-55.
13. Pellagatti A, Hellstrom-Lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal and translation-related genes. Br J Haematol. 2008; 142(1):57-64.
14. Wang L, Fidler C, Nadig N, Giagounidis A, Della Porta MG, Malcovati L, et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica. 2008;93(7):994-1000.
15. Boultwood J. The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome. Pediatr Rep. 2011;3(Suppl. 2):e10.
16. Zhou X, Hao Q, Liao J, Zhang Q, Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 2013;32(3):388-96.
17. Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Lagana C, et al. Changes in RPS14 expression levels during lena-lidomide treatment in low and intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol. 2010;85(3):231-5.
18. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell. 2002; 110(1):9-12.
19. Wu Q, Gou Y, Wang Q, Jin H, Cui L, Zhang Y, et al. Downregulation of RPL6 by siRNA inhibits proliferation and cell cycle progression of human gastric cancer cell lines. PLoS ONE. 2011;6(10):e26401.
20. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86(1):268-76.
21. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology. 2002;181-182:475-81.
22. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393):1497-501.
23. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol. 2000;20(12):4210-23.